Sweat secretion rates in growth hormone disorders. 2000

S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
Department of Endocrinology, Rigshospitalet, The National University Hospital, Copenhagen, Denmark.

BACKGROUND While increased sweating is a prominent symptom in patients with active acromegaly, reduced sweating is gaining status as part of the growth hormone deficiency (GHD) syndrome. METHODS Sweat secretion rate (SSR), as measured by pilocarpine iontophoresis represents the maximal capacity for stimulated sweat secretion in a localized skin area. SSR was studied in 37 patients with a history of acromegaly, 20 adult patients with GHD before and during long-term GH substitution of GHD adults, and 58 control subjects. RESULTS Acromegaly: Patients with acromegaly had significantly higher SSR than healthy controls (Z-score + 1.9 (+/- 1.1) mean (+/- SD) (P < 0.001)). SSR was increased irrespective of current clinical disease activity. Thus, the SSR Z-scores in 16 clinically inactive patients were + 2.1 (+/- 1.2), in 10 slightly or doubtfully active patients + 1.5 (+/- 0.7) and in 11 active patients + 1.8 (+/- 1.3). There was no correlation between SSR and IGF-I. GHD: Twenty adult patients participated in an 18-month randomised, placebo controlled, double blinded study of physiological dose GH substitution, followed by 18 months of open GH treatment. SSR at baseline was reduced in male but not in female GHD patients. Mean SSR (95% confidence interval) for 11 male patients was 89.0 mg/30 minutes (51.9-126.1) as compared to 133.5 mg/30 minutes (59.2-259.9) (P = 0.01) in 24 male controls, and for 11 female patients 48.2 mg/30 minutes (25.9-70.6) as compared to 49.2 mg/30 minutes (12.6-93. 9) in 34 female controls. GH treatment in physiological substitution doses for up to 36 months had no effect on SSR. CONCLUSIONS We have demonstrated that longstanding GH hypersecretion in patients with acromegaly induces irreversible changes of sweat gland function, with persistently elevated SSR despite treatment and clinical cure. In GHD patients, SSR was reduced in males but not in females, which together with the established gender difference in normal controls emphasises the role of androgen deficiency as a cofactor for reduced sweating in hypopituitary patients. Sweat gland development seems to be more susceptible to lack of hormones in childhood and adolescence than in adulthood, whereas growth hormone excess can modify sweat function later in life.

UI MeSH Term Description Entries
D007007 Hypohidrosis Abnormally diminished or absent perspiration. Both generalized and segmented (reduced or absent sweating in circumscribed locations) forms of the disease are usually associated with other underlying conditions. Anhidrosis
D007018 Hypopituitarism Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions. Adenohypophyseal Hyposecretion,Anterior Pituitary Hyposecretion Syndrome,Sheehan Syndrome,Simmonds Disease,Hyposecretion Syndrome, Anterior Pituitary,Hyposecretion, Adenohypophyseal,Pituitary Insufficiency,Postpartum Hypopituitarism,Postpartum Panhypopituitarism,Postpartum Pituitary Insufficiency,Sheehan's Syndrome,Simmonds' Disease,Disease, Simmonds,Hypopituitarism, Postpartum,Insufficiency, Pituitary,Panhypopituitarism, Postpartum,Pituitary Insufficiency, Postpartum,Sheehans Syndrome,Simmond's Disease,Syndrome, Sheehan,Syndrome, Sheehan's
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D007478 Iontophoresis Therapeutic introduction of ions of soluble salts into tissues by means of electric current. In medical literature it is commonly used to indicate the process of increasing the penetration of drugs into surface tissues by the application of electric current. It has nothing to do with ION EXCHANGE; AIR IONIZATION nor PHONOPHORESIS, none of which requires current. Iontophoreses
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006945 Hyperhidrosis Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise. Hyperidrosis
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)

Related Publications

S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
January 1971, Journal of animal science,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
January 1981, Advances in biochemical psychopharmacology,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
January 1981, Srpski arhiv za celokupno lekarstvo,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
February 1970, Endocrinology,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
February 1985, Clinics in endocrinology and metabolism,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
September 1979, Wiadomosci lekarskie (Warsaw, Poland : 1960),
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
January 1954, Langenbecks Archiv fur klinische Chirurgie ... vereinigt mit Deutsche Zeitschrift fur Chirurgie,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
January 2011, International journal of endocrinology,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
June 1973, Horumon to rinsho. Clinical endocrinology,
S B Sneppen, and K M Main, and A Juul, and L M Pedersen, and L O Kristensen, and N E Skakkebaek, and U Feldt-Rasmussen
January 1987, Pediatrician,
Copied contents to your clipboard!